Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705547 · ClinicalTrials.gov registry record · Early Phase 1
Rosuvastatin (Crestor) in Friedreich Ataxia
A Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT02705547 is a Early Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 12 participants.
The verdict
NCT02705547, a Early Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.
Interventions
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-08-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02705547
The ClinicalTrials.gov registry entry for NCT02705547 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin is the first listed.
NCT02705547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02705547 about?
NCT02705547 is a clinical study titled "Rosuvastatin (Crestor) in Friedreich Ataxia". This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvasta...
What is the current status of trial NCT02705547?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2016-05. Estimated completion is 2017-08-04.
What interventions are being tested in trial NCT02705547?
The interventions under investigation include: Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT02705547?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.